GENERAL ORTHOPAEDICS
COA: Extended thromboprophylaxis effective following hip fracture surgery
509 patients who had undergone hip fracture surgery received daily open-label semuloparin injections for 7-10 days following surgery (run-in phase). Afterwards, 469 patients were randomized to receive either semuloparin injections or placebo injections for 19-23 days, to compare the safety and efficacy of extended thromboprophylaxis. Following 24 days results indicated that extended thromboprophylaxis with semuloparin was significantly more effective than the placebo in lowering the occurrence of venous thromboembolism or all-cause death. However, there were 2 bleeding events reported in the semuloparin group.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
